Hikma Farmacêutica (Portugal) S.A has informed the MHRA that the Patient Information Leaflet (PIL) contained within batch CB0033 of Gemcitabine 2g/52.6ml concentrate for solution for infusion does not contain the side effects of serious skin reactions.
Similar Posts
European first as MHRA approves over-the-counter allergy treatment for adolescents aged 12 and over
As with any medicine, the MHRA will keep the safety and effectiveness of fluticasone propionate under close review.
Field Safety Notices: 18 to 22 August 2025
List of Field Safety Notices from 18 to 22 August 2025.
Class 4 Medicines Defect Notification: Fexofenadine Hydrochloride 120mg film-coated tablets, Chanelle Medical Unlimited Company, EL(25)A/41
Chanelle Medical Unlimited Company has informed the MHRA of an error with the European Article Number (EAN) / Global Trade Item Number (GTIN) barcode on certain batches of Fexofenadine Hydrochloride 120mg film-coated tablets, distributed by Healthcare Pharma Limited.
Transparency data: Medicines and Healthcare products Regulatory Agency GPC spending over £500: 2024-25
MHRA transactions over £500 made using the government procurement card (GPC).
Precautionary recall of blood pressure medication after packaging error
The MHRA has advised pharmacy and healthcare professionals to return all remaining stock to their suppliers
Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell▼): updated safety and educational materials to support patient discussion on reproductive risks
Updated safety and educational materials are now available to support the implementation of the regulatory measures announced in the November 2023 National Patient Safety Alert and the September 2024 Drug Safety Update. They also include previous updates to product information on the risk of low birth weight in children exposed to valproate during pregnancy.